NATALIE MARSHALL: Open Payments
NPI 1548739451 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,229 in 128 payments from 20 companies in 2025. Trend: 2023 $2,048 · 2024 $1,474 · 2025 $2,229
Food & beverage: $2,229
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 27 | $383 |
| Incyte Corporation | 20 | $342 |
| ABBVIE INC. | 9 | $184 |
| GENZYME CORPORATION | 10 | $165 |
| Galderma Laboratories, L.P. | 15 | $164 |
| Amgen Inc. | 5 | $121 |
| Novartis Pharmaceuticals Corporation | 6 | $120 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 4 | $103 |
| UCB, Inc. | 4 | $98 |
| Lilly USA, LLC | 4 | $94 |
Products named: TREMFYA, OPZELURA, DUPIXENT, SKYRIZI, OTEZLA, ILUMYA, Bimzelx, TALTZ.
Industry payments across TX — which companies pay providers there.
